Correction (DOI:10.1016/j.ahj.2009.07.001);The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) trial: study design and rationale

American Heart Journal

Volumn 158, Issue 3, 2009, Pages 334.e4-

  Harrington, Robert A ^a   Van De Werf, Frans ^b   Armstrong, Paul W ^c   Aylward, Phil ^d   Veltri, Enrico ^e   Mahaffey, Kenneth W ^a   Moliterno, David J ^f   Strony, John ^e   Wallentin, Lars ^g   White, Harvey D ^h   Diaz, Rafael ⁱ   Huber, Kurt ^j   Nicolau, Jose Carlos ^k   Prieto, Juan Carlos ^l   Isaza, Daniel ^m   Widimsky, Petr ⁿ   Grande, Peer ^o   Nieminen, Markku ^p   Montalescot, Gilles ^q   Bode, Christoph ^r   Wong, Lawrence ^s   Ofner, Peter ^t   Lewis, Basil S ^u   Ambrosio, Giuseppe ^v   Valgimigli, Marco ^w   Ogawa, Hisao ^x   Yamaguchi, Jun Ichi ^y   Jukema, J Wouter ^z   Cornel, Jan H ^aa   Nordrehaug, Jan Erik ^ab   Ruzyllo, Witold ^t   Providencia, Luis ^ac   Tan, Huay Cheem ^ad   Dalby, Anthony ^ae   Park, Seung Jung ^af   Betriu, Amadeo ^ag   Cequier, Angel ^ag   Held, Claes ^g   Pfisterer, Mathias ^ah   Chen, Ming Fong ^ai   Timurkaynak, Timur ^aj   Storey, Robert F ^ak   Chen, Edmond ^e   Hudson, Michael P ^al   Lincoff, A Michael ^am   Morrow, David A ^an   Tricoci, Pierluigi ^a   Whellan, David ^ao   Verheugt, Freek ^ap   Frye, Robert L ^aq   Hochman, Judith ^ar   Steg, Philippe Gabriel ^as   Bailey, Kent R ^aq   more..

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ALBERTA   (Canada)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e MERCK RESEARCH LABORATORIES   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^h Cardiovascular Service   (New Zealand)

ⁱ Instituto Cardiovascular de Rosario ^*  (Argentina)

^j WILHELMINEN HOSPITAL   (Austria)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^m Fundación Clínica Shaio   (Colombia)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o Mental Health Services CPH   (Denmark)

^p HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^q PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^r UNIVERSITY OF FREIBURG   (Germany)

^s CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^t National Institute of Cardiology Budapest   (Hungary)

^u CARMEL MEDICAL CENTER   (Israel)

^v UNIVERSITY OF PERUGIA   (Italy)

^w UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^x KUMAMOTO UNIVERSITY   (Japan)

^y TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^z LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^aa Location Alkmaar   (Netherlands)

^ab UNIVERSITY OF BERGEN   (Norway)

^ac UNIVERSITY OF COIMBRA   (Portugal)

^ad NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^ae UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^af Asan Medical Center   (South Korea)

^ag UNIVERSITY OF BARCELONA   (Spain)

^ah UNIVERSITY HOSPITAL BASEL   (Switzerland)

^ai NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^aj GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^ak UNIVERSITY OF SHEFFIELD   (United Kingdom)

^al HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^am LERNER RESEARCH INSTITUTE   (United States)

^an BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ao THOMAS JEFFERSON UNIVERSITY   (United States)

^ap RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^aq MAYO CLINIC   (United States)

^ar NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^as BICHAT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; RIFAMPICIN; SCH 530348; THROMBIN INHIBITOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; STROKE;

EID: 68949131480     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.03.003     Document Type: Erratum

References (38)

1. Tricoci P., Roe M.T., Mulgund J., et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 166 (2006) 806-811
2. Mahaffey K.W., Cohen M., Garg J., et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 294 (2005) 2594-2600
3. Steg P.G., Goldberg R.J., Gore J.M., et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90 (2002) 358-363
4. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28 (2007) 1598-1660
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
6. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
7. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
8. Rao S.V., O'Grady K., Pieper K.S., et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47 (2006) 809-816
9. Eikelboom J.W., Mehta S.R., Anand S.S., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
10. Rao S.V., O'Grady K., Pieper K.S., et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
11. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
12. Chackalamannil S., Davies R.J., Asberom T., et al. A highly efficient total synthesis of (+)-himbacine. J Am Chem Soc 118 (1996) 9812-9813
13. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
14. Sutton A.J., Cooper N.J., Abrams K.R., et al. A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. J Clin Epidemiol 58 (2005) 26-40
15. Bhatt D.L., Fox K.A.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
16. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
17. Anderluh M., and Dolenc M.S. Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr Med Chem 9 (2002) 1229-1250
18. Andersen H., Greenberg D.L., Fujikawa K., et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96 (1999) 11189-11193
19. Leger A.J., Covic L., and Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 114 (2006) 1070-1077
20. Eikelboom J.W., Weitz J.I., Budaj A., et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 23 (2002) 1771-1779
21. Kleiman N.S., Tracy R.P., Talley J.D., et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 9 (2000) 5-12
22. Kato Y., Kita Y., Hirasawa-Taniyama Y., et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 473 (2003) 163-169
23. Doller D., Chackalamannil S., Czarniecki M., et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett 9 (1999) 901-906
24. Derian C.K., Damiano B.P., Addo M.F., et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304 (2003) 855-861
25. Becker R.C., Moliterno D.J., Jennings L.K., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373 (2009) 919-928
26. Chintala M., Vemulapalli S., Kurowski S., et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Abstract submitted to Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference; April 16-18 (2008)
27. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
28. Morrow D.A., Scirica B.M., Fox K.A.A., et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 Trial. Am Heart J 158 (2009) 335-341
29. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009) 2176-2190
30. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157
31. Okamatsu K., Takano M., Sakai S., et al. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation 109 (2004) 465-470
32. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
33. Alter D.A., Manuel D.G., Gunraj N., et al. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. Am J Med 116 (2004) 540-545
34. Thygesen K., Alpert J.S., White H.D., and Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 50 (2007) 2173-2195
35. Rao S.V., Jollis J.G., Harrington R.A., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
36. Goto S., Tamura N., Eto K., et al. Functional significance of adenosine 5′-diphosphate receptor (P2Y[12]) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 105 (2002) 2531-2536
37. Maurice P., Legrand C., and Fauvel-Lafeve F. Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen. FASEB J 18 (2004) 1339-1347
38. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216